Breaking News, Collaborations & Alliances

Adaptive Biotechnologies, Takeda to Measure Minimal Residual Disease with clonoSEQ Assay

Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company, entered into a translational collaboration with Takeda to use its clonoSEQ Assay to assess minimal residual disease (MRD) to facilitate the development and commercialization of Takeda’s pipeline of treatments for patients with lymphoid malignancies. “We are thrilled to enter into a broad translational collaboration with Takeda incorporating the use of our clonoSEQ Assay technology in clinical trials to support the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters